Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
IL21R antisense RNA 1 (non-protein coding) (IL21R-AS1)
- Target
- IL21R-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Other
01
Overview
IL21R antisense RNA 1 (IL21R-AS1) is a long non-coding RNA located at chromosome 4q27, acting in the nucleus where it likely regulates gene expression—most notably, it modulates the nearby IL21 receptor gene. It is differentially expressed in several disease states including coronary artery disease, systemic lupus erythematosus, and rheumatoid arthritis, and may regulate immune and inflammatory pathways, possibly via the IL-2/T follicular regulatory (Tfr) cell axis. Its precise molecular mechanism remains unclear, but research indicates potential as a non-invasive biomarker for immune-mediated diseases and vascular pathologies. Direct pharmacological targeting is not established, though modulation of its levels could theoretically influence disease activity.
- Other names
- IL21R antisense RNA 1IL21R-AS1IL21R antisense RNA 1 (non-protein coding)
02
Mechanism of action
Not applicable (no established drug mechanism as it is not a classical target)
03
Biological functions
Regulation of gene expression (especially modulation of the nearby IL21 receptor gene)Immune response modulationRegulation of inflammationNuclear enrichment (suggested to function primarily in the nucleus)
04
Disease associations
Autoimmune disease (such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA))Cardiovascular disease (coronary artery disease (CAD))
05
Safety considerations
Not established (no direct targeting; general research on lncRNA modulation may present off-target or unknown biological risks)
06
Biomarkers
Differential expression in plasma and monocytes used as a circulating biomarker for coronary artery disease (CAD)Reduced expression in PBMCs and CD4+ T cells is linked to SLE and RA disease activity
Beyond the preview
Go deeper on IL21R antisense RNA 1 (non-protein coding) (IL21R-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL21R antisense RNA 1 (non-protein coding) (IL21R-AS1).